Sanofi has entered into an agreement to acquire US-based Protein Sciences in a deal worth up to US$750 M. The acquisition will diversify Sanofi’s vaccine portfolio with the addition of Protein Sciences’ egg-free influenza vaccine, Flublok Quadrivalent, the only FDA approved recombinant protein-based influenza seasonal influenza vaccine available in the US.